Koštani markeri su veoma korisno dijagnostiško sredstvo, mada je njihova klinička upotreba ograničena specifičnim tehničkim i analitičkim aspektima, kao i njihovom pre-analitičkom varijabilnošću. Koštani markeri, za razliku od mineralne gustine kosti, ukazuju na posebne aspekte kvaliteta kostiju, te stoga nude zasebnu i prognostičku perspektivu u ispitivanju promena mineralne gustine kosti I smanjivanju rizika od fraktura. Smanjenje nivoa koštanih markera usko je povezano sa smanjenjem rizika od frakture vratnih pršljenova usled korišćenja raloksifena, rizedronata i alendronata. Postoje brojne mogućnosti za korišćenje ovih markera u kratkoročnom praćenju toka lečenja osteoporoze, pored merenja mineralne koštane gustine, kako bi se otkrili pacijenti koji ne reaguju na terapiju.
Michalska D, Stepan JJ, Basson BR, Pavo I. The effect of raloxifene following the discontinuation of long-term alendronate treatment of postmenopausal osteoporosis. Journal of Clinical Endocrinology & Metabolism. 2006;91(3):870–7.
2.
Wasnich RD, Miller PD. Antifracture efficacy of antiresorptive agents are related to changes in bone density. Journal of Clinical Endocrinology & Metabolism. 2000;85(1):231–6.
3.
Wasnich R, Miller PD, Huss H, Chesnut CH, Wilson K, Schimmer RC. Association between fracture efficacy and bone mineral density change with ibandronate: Results from the BONE Study. Osteoporosis International. 2003;14(Suppl 7):76.
4.
Stepan JJ. Klinička vrednost biohemijskih markera za remodeliranje kostiju u ispitivanju bolesti koštanog metabolizma. Jugoslovenska Medicinska Biohemija. 2006;25(3):241–8.
5.
Stepan JJ. Prediction of bone loss in postmenopausal women. Osteoporosis International. 2000;11(Suppl 6):45–54.
6.
Stepan JJ, Vokrouhlicka J. Comparison of biochemical markers of bone remodelling in the assessment of the effects of alendronate on bone in postmenopausal osteoporosis. Clinica Chimica Acta. 1999;288(1–2):121–35.
7.
Stepan J, Michalska D, Zikan V, Vokrouhlicka J. Biochemical markers of type I collagen synthesis and degradation in monitoring osteoporosis treatment with raloxifene and alendronate. Journal of Bone and Mineral Research. 2002;17(Suppl 1):233.
8.
Smilić L. Mehaničke i endokrine manifestacije na koštanom sistemu kod gojaznih. 2010.
9.
Sarkar S, Reginster J, Crans GG, Diez-Perez A, Pinette KV, Delmas PD. Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk. Journal of Bone and Mineral Research. 2004;19(3):394–401.
10.
Riggs BL, Melton LJ, O’Fallon WM. Drug therapy for vertebral fractures in osteoporosis: Evidence that decreases in bone turnover and increases in bone mass both determine antifracture efficacy. Bone. 1996;18(3 Suppl):197–201.
11.
Ravn P, Clemmesen B, Christiansen C. Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Bone. 1999;24(3):237–44.
12.
Nielsen NM, Recke P, Hansen MA, Overgaard K, Christiansen C. Estimation of the effect of salmon calcitonin in established osteoporosis by biochemical bone markers. Calcified Tissue International. 1994;55(1):8–11.
13.
Bauer DC, Black DM, Garnero P, Hochberg M, Ott S, Orloff J, et al. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: The fracture intervention trial. Journal of Bone and Mineral Research. 2004;19(8):1250–8.
14.
Mazzuoli G, Acca M, Pisani D, Diacinti D, Scarda A, Scarnecchia L, et al. Annual skeletal balance and metabolic bone marker changes in healthy early postmenopausal women: Results of a prospective study. Bone. 2000;26(4):381–6.
15.
Kraenzlin ME, Seibel MJ, Trechsel U, Boerlin V, Azria M, Kraenzlin. The effect of intranasal salmon calcitonin on postmenopausal bone turnover as assessed by biochemical markers: Evidence of maximal effect after 8 weeks of continuous treatment. Calcified Tissue International. 1996;58(4):216–20.
16.
Gerdhem P, Ivaska KK, Alatalo SL, Halleen JM, Hellman J, Isaksson A, et al. Biochemical markers of bone metabolism and prediction of fracture in elderly women. Journal of Bone and Mineral Research. 2004;19(3):386–93.
17.
Garnero P, Mulleman D, Munoz F, Sornay-Rendu E, Delmas PD. Long-term variability of markers of bone turnover in postmenopausal women and implications for their clinical use: The OFELY study. Journal of Bone and Mineral Research. 2003;18(10):1789–94.
18.
Garnero P. Markers of bone turnover for the prediction of fracture risk. Osteoporosis International. 2000;11(Suppl 6):55–65.
19.
Frost ML, Fogelman I, Blake GM, Marsden PK, Cook G. Dissociation between global markers of bone formation and direct measurement of spinal bone formation in osteoporosis. Journal of Bone and Mineral Research. 2004;19(11):1797–804.
20.
Durham LH, Willatt DJ, Yung MW, Jones I, Stevenson PA, Ramadan MF. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. Journal of Bone and Mineral Research. 2003;18(6):1051–6.
21.
Delcker A, Diener HC, Wilhelm H. Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy. Bone. 2004;34(4):599–604.
22.
Rio FMC, Frutos AJF, Gonzalez GJI, Bellido CJ, Marcos ML, Fernandez RA. Monitoring individual response to hormone replacement therapy with bone markers. Bone. 2000;26(6):553–60.
23.
Bjarnason NH, Bjarnason K, Hassager C, Christiansen C. The response in spinal bone mass to tibolone treatment is related to bone turnover in elderly women. Bone. 1997;20(2):151–5.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
